CoChat

Frequently asked questions to the 2023 Obesity Medicine Association Position Statement on Compounded Peptides: A call for action

Open access
Bays, Harold Edward, Fitch, Angela, Francavilla Brown, Carolynn, Younglove, Courtney, Christensen, Sandra M., Alexander, Lydia C. · 2024 · Obesity Pillars
Cited by 16

The DOI matches its Crossref record.

Abstract

Background: In 2023, the Obesity Medicine Association (OMA) published "Compounded peptides: An Obesity Medicine Association Position Statement." Since this publication, the use of compounded peptides for the treatment of obesity has continued to evolve, leading to additional confusion and questions from obesity medicine clinicians and their patients. Methods: This frequently asked questions (FAQ) document and "Call for Action" commentary is based upon the existing evidence and practical clinical experiences of the authors. Results: This FAQ is intended to provide insights beyond the original 2023 OMA Position Statement regarding the use of "compounded peptides" for treating obesity. Three obstacles impair patient access to highly effective peptide anti-obesity medications: insufficient production especially during times of high demand, high costs, and lack of clarity surrounding the role of compounded peptides. Solutions to enhance patient access to these medications lie within the existing legal and regulatory framework and Food and Drug Administration policies. Implementing these solutions necessitates dispelling misinformation and providing clear guidance on the appropriate prescribing and administration of compounded peptides, particularly during times of acknowledged shortage. Conclusion: Among stakeholders with aligned priorities, challenges can often be overcome by collaboration and communication. Towards the goal of providing patient-centered care, the OMA calls on applicable stakeholders (e.g., pharmaceutical companies, compounding pharmacy organizations, health insurance companies, and the Food and Drug Administration) to work collaboratively to achieve a consensus that improves patient access to safe anti-obesity medications. The purpose of this "Call to Action" is to ask stakeholders to provide clinicians and their patients clarity regarding the role of compounded peptide anti-obesity medications during times of FDA-acknowledged shortages. Finally, this FAQ review provides clinicians with a simple and practical checklist respective to the potential use of compounded peptides.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.obpill.2024.100122

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 2

  1. Fitch, 2023, Compounded peptides: an obesity medicine association position statement, Obesity Pillars, 6, 10.1016/j.obpill.2023.100061 · DOI
  2. Gianturco, 2003, Distinguishing between compounding facilities and the development of the 503B bulk drug substance list, J Am Pharm Assoc JAPhA, 61, e8, 10.1016/j.japh.2020.06.024 · doi:10.1016/j.japh.2020.06.024

Cited by

See all 16

Metadata

Authors
Bays, H. E., Fitch, A., Francavilla Brown, C., Younglove, C., Christensen, S. M., & Alexander, L. C.
Venue
Obesity Pillars
Publisher
Elsevier BV
Published
2024-09
Volume
11
Pages
100122
ISSN
2667-3681 (ISSN-L)
OpenAlex
W4401147691
Cited by
16
References
0
FWCI
3.30
Type
journal article
Language
en
Open access
gold
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Frequently asked questions to the 2023 Obesity Medicine Association Position Statement on Compounded Peptides: A call for action. https://app.cochat.ai/papers/10.1016/j.obpill.2024.100122
The paper
Bays, H. E., Fitch, A., Francavilla Brown, C., Younglove, C., Christensen, S. M., & Alexander, L. C. (2024). Frequently asked questions to the 2023 Obesity Medicine Association Position Statement on Compounded Peptides: A call for action. Obesity Pillars. https://doi.org/10.1016/j.obpill.2024.100122

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.